Clinical trial
Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of…
NCT00496015 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00496015 |
|---|---|
| Title | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A |
| Official title | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal |
| Intervention type | Biological, Drug |
| Interventions | Pneumococcal conjugate vaccine GSK1024850A., Infanrix hexa., Meningococcal vaccine GSK134612., Paracetamol. |
| Enrollment | 750 |
| Start date | Jul 2, 2007 |
| Primary completion | Mar 25, 2008 |
| Completion | Feb 17, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Jan 18, 2019 |
| Countries | Czechia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: